GSK shares dive as weaker sales and mounting costs unnerve investors

Sources

Coverage

Limited spectrum

Sentiment

0.00

◀ Left 100%Centre 0%Right 0% ▶

How we rate bias →

This story is currently only covered by one source from a single part of the political spectrum. NewsDeck will update this page automatically if other outlets pick up the story.

shopping_bagNoise-Cancelling Headphones

Good for political podcasts and audiobooks on the commute.

Browse headphones on Amazonarrow_forward

NewsDeck Poll

Do you think this story is being covered fairly across the political spectrum?

Loading…

Left

(1)

Guardian Business

GSK shares dive as weaker sales and mounting costs unnerve investors

British pharma company reports declining profits amid weaker vaccine sales and looming patent loss for blockbuster HIV drug Business live – latest updates Shares in GSK slid on Wednesday despite the UK drugmaker reporting better than expected financial results, as investors were unnerved by weaker vaccine sales, restructuring charges and its overall outlook. Britain’s second-biggest pharmaceutical company reported …